Details of the Drug Combination

General Information of Drug Combination (ID: DCYVHUL)

Drug Combination Name
Taxol ER819762
Indication
Disease Entry Status REF
Mixed endometrioid and clear cell carcinoma Investigative [1]
Component Drugs Taxol   DMUOT9V ER819762   DMSG91J
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL is unavailable 3D MOL is unavailable
High-throughput Screening Result Testing Cell Line: IGROV1
Zero Interaction Potency (ZIP) Score: 6.47
Bliss Independence Score: 7.07
Loewe Additivity Score: 2.18
LHighest Single Agent (HSA) Score: 6.68

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Taxol
Disease Entry ICD 11 Status REF
Breast cancer 2C60-2C65 Approved [2]
Solid tumour/cancer 2A00-2F9Z Approved [3]
Pancreatic cancer 2C10 Phase 3 [4]
Gastric adenocarcinoma 2B72 Phase 2 [5]
Ovarian cancer 2C73 Phase 2 [5]
Taxol Interacts with 2 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Apoptosis regulator Bcl-2 (BCL-2) TTJGNVC BCL2_HUMAN Modulator [2]
Tubulin beta (TUBB) TTYFKSZ NOUNIPROTAC Modulator [2]
------------------------------------------------------------------------------------
Indication(s) of ER819762
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [6]
ER819762 Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Prostaglandin E2 receptor EP4 (PTGER4) TT79WV3 PE2R4_HUMAN Antagonist [7]
------------------------------------------------------------------------------------

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Adult T acute lymphoblastic leukemia DCDH3PT MOLT-4 Investigative [8]
Childhood T acute lymphoblastic leukemia DCS3FJZ CCRF-CEM Investigative [8]
Chronic myelogenous leukemia DCF24Y5 K-562 Investigative [8]
Invasive ductal carcinoma DCLZ4SC T-47D Investigative [9]
Adenocarcinoma DC0WOTD OVCAR3 Investigative [1]
Adenocarcinoma DC3QI2D A549 Investigative [1]
Adenocarcinoma DCYGAN9 HCT116 Investigative [1]
Large cell lung carcinoma DCHRBXU NCI-H460 Investigative [1]
Lung adenocarcinoma DCSKCEG HOP-62 Investigative [1]
Malignant melanoma DC7N4W0 LOX IMVI Investigative [1]
Prostate carcinoma DCROJ5R PC-3 Investigative [1]
------------------------------------------------------------------------------------
⏷ Show the Full List of 11 DrugCom(s)

References

1 Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
2 Paclitaxel directly binds to Bcl-2 and functionally mimics activity of Nur77. Cancer Res. 2009 Sep 1;69(17):6906-14.
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
6 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4040).
7 A novel antagonist of the prostaglandin E(2) EP(4) receptor inhibits Th1 differentiation and Th17 expansion and is orally active in arthritis models. Br J Pharmacol. 2010 May;160(2):292-310.
8 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
9 Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.